Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 June 2019 | Story Valentino Ndaba | Photo Albert van Biljon
Alison Botha
Over and above being a survivor, Alison Botha is an inspiration.

It was an ordinary December 1994 evening in Port Elizabeth. Alison Botha parked her car in front of her home. A man ambushed her at knife point. Minutes later, she was forced into the passenger seat and the perpetrator drove off, picking his friend up on their way to the coastal bushes of the city.
 
What was supposed to be an ordinary evening turned into a horrific experience which changed Botha’s life forever. She was raped, strangled, had her throat slit and her stomach cut open. Physicians called her survival a medical miracle. The true miracle though, is how she has chosen to deal with the experience. 

Botha overcame her fear of public speaking and has become an international motivational speaker who also authored a first-person account of her ordeal and recovery in 1998, titled I Have Life.

Aluta continua against gender-based violence

As part of our university’s advocacy against gender-based violence, the Human Resources’ Division for Organisational Development and Employee Wellness hosted Botha for a motivational talk on 5 June 2019 at the Bloemfontein Campus. In telling her story, Botha stated that she still receives healing.

While welcoming guests and the speaker, Prof Prakash Naidoo, Vice-Rector: Operations touched on Project Caring which is supported by the Rectorate. “We care for you and part of that caring agenda is gender-based violence. We encourage you to speak out about this issue, don’t remain silent, someone will listen,” he advised.

From victim to victor

Botha believes that if her story serves to help someone else avoid the same situation or perhaps even survive a similar trauma, then she has served her purpose. “I now believe that the evil is far outweighed by all the good that has come out of my choice to share my story,” she said.

Much of the reason behind her strength lies in what she terms her own ABC principle which speaks to attitude, belief and choice. “We are not always going to be in control of everything that happens to us. But we always control how we respond,” said Botha. 

The story of Botha’s survival, recovery and victory proves that the human spirit cannot be crushed. There is indeed life after a near-death tragedy.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept